SCHEMBL2260701

SCHEMBL2260701

COC(=O)c1cc(-c2ccc(C)cc2F)nc(N2CCOCC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.51
PIK3CB P42338 2/20 0.51
PIK3CG P48736 3/20 0.44
AURKA O14965 2/20 0.43
RAF1 P04049 2/20 0.43
BRAF P15056 2/20 0.43
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
KDM4E B2RXH2 3/20 0.42
AKT1 P31749 3/20 0.42
PIK3CD O00329 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260307 0.88 PIK3CA (0.50) PIK3CAPIK3CGRAF1BRAFALDH1A1
SCHEMBL2259992 0.77 NPC1 (0.38) PIK3CAPIK3CBPIK3CGRAF1BRAF
SCHEMBL16440127 0.77 NPC1 (0.38) PIK3CAPIK3CBPIK3CGRAF1BRAF
SCHEMBL19367477 0.77 PIK3CA (0.60) PIK3CAPIK3CBPIK3CGAURKAALDH1A1
SCHEMBL2260726 0.76 CYP46A1 (0.45) ALDH1A1SMN1; SMN2KDM4EHPGDMEN1
SCHEMBL23259072 0.76 PIK3CA (0.54) PIK3CAPIK3CBPIK3CGAURKAALDH1A1
SCHEMBL17607788 0.74 PIK3CA (0.58) PIK3CAPIK3CBPIK3CGAURKAALDH1A1
SCHEMBL1579169 0.74 PIK3CA (0.58) PIK3CAPIK3CBPIK3CGAURKARAF1
SCHEMBL34470594 0.71 GSK3B (0.43) PIK3CAPIK3CBRAF1
SCHEMBL31330481 0.70 P2RX7 (0.39) PIK3CAPIK3CBRAF1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2860178-B1 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME (US) 2021-01-13 EP disclosed
EP-2860178-A2 P2X3 receptor antagonists for treatment of pain Merck Sharp & Dohme Corp. (US) 2015-04-15 EP disclosed
EP-2358371-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2015-02-11 EP disclosed
US-8598209-B2 P2X3, receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2013-12-03 US disclosed
US-20110206783-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME LLC 2011-08-25 US disclosed
EP-2358371-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2011-08-24 EP disclosed
WO-2010051188-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206783-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 PIK3CA 1308/4885PIK3CB 1599/4885PIK3CG 1425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.